Reata Pharmaceuticals, a Brooklyn-based company, has recently been acquired by Biogen, a leading biotechnology company. Specializing in the field of Friedreich's Ataxia (FA), Reata Pharmaceuticals focuses on providing genetic testing and optimal supportive care for patients with this progressively degenerative disease. They emphasize the importance of early diagnosis through genetic testing and the need for a multidisciplinary care team to address the multisystem nature of FA. Additionally, they highlight the significance of the modified Friedreich's Ataxia Rating Scale (mFARS) in assessing the disease's progression and its impact on patient function.
Generated from the website